Cyril Amarchand Mangaldas Advised Akums Drugs & Pharmaceuticals On ₹18,567.37 Million IPO
Cyril Amarchand Mangaldas advised Akums Drugs & Pharmaceuticals Ltd (the Company) as their legal counsel on matters of
Cyril Amarchand Mangaldas Advised Akums Drugs & Pharmaceuticals On ₹18,567.37 Million IPO
Cyril Amarchand Mangaldas advised Akums Drugs & Pharmaceuticals Ltd (the Company) as their legal counsel on matters of Indian law for their initial public offering (IPO) of 27,368,151 equity shares, totaling ₹18,567.37 million (the Offer).
The Offer consisted of a fresh issue of 10,037,716 equity shares, amounting to ₹6,800 million, and an offer for sale of 17,330,435 equity shares, aggregating to ₹11,767.37 million by the Promoters of the Company and Ruby QC Investment Holdings Pte. Ltd (Quadria Capital).
The Offer opened on July 30, 2024, and closed on August 1, 2024. It was oversubscribed by nearly 63 times, with the portion reserved for qualified institutional buyers being subscribed by more than 90 times.
The Book Running Lead Managers to the Offer were ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited.
The transaction team from Cyril Amarchand Mangaldas was led by Partner and Head of Capital Markets, Yash J. Ashar, along with Partner Gokul Rajan, Principal Associate Nayan Jain, Senior Associate Chinar Gupta, and Associates Rajshree Agarwal, Shreya Jain, Waleed Nazir Latoo, Vatsala Parashar, and Tara Thakur.